Distinct differences in serum eicosanoids in healthy, enteritis and colorectal cancer individuals

Zhang, Junjie; Yang, Qingjin; Li, Jian; Zhong, Yu; Zhang, Lijian; Huang, Qionglin; Cui, Bin; Mo, Mingming; Shen, Sensen; Zhong, Qisheng; Liu, Huwei; Cai, Chun

doi:10.1007/s11306-017-1293-9

Cited by 16 publications

(10 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is noteworthy that the plasma levels of eicosanoids and related mediators were decreased, without any changes of the plasma AA, EPA, and DHA levels. These results were concordant with a previous study conducted using the serological samples of human subjects with colorectal cancer, 60 while partially contradicting previous reports indicating that the levels of AA derivatives were higher, while those of linoleic acid derivatives were lower in serum samples collected from subjects with colorectal cancer. 61 Considering that the levels of eicosanoids and related mediators are substantially influenced by platelet activation, we believe that their levels would decrease in circulation, although the precise mechanisms remain unclear.…”

Section: Discussionsupporting

confidence: 81%

Understanding modulations of lipid mediators in cancer using a murine model of carcinomatous peritonitis

2022

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 81%

Understanding modulations of lipid mediators in cancer using a murine model of carcinomatous peritonitis

2022

View full text Add to dashboard Cite

show abstract

“…Whenever possible, performance characteristics were extracted with a healthy control group as the reference group. One study only used diseased controls [ 18 ], and some studies additionally combined healthy individuals with people with benign colorectal diseases [ 19 , 20 , 21 , 22 ]. Uchiyama et al combined carriers of adenomas with healthy controls to distinguish from CRC cases but reported on characteristics to distinguish adenomas from healthy controls as well [ 23 ].…”

Section: Resultsmentioning

confidence: 99%

Metabolomics Biomarkers for Detection of Colorectal Neoplasms: A Systematic Review

Erben

Bhardwaj

Schrotz‐King

et al. 2018

Cancers

View full text Add to dashboard Cite

Background: Several approaches have been suggested to be useful in the early detection of colorectal neoplasms. Since metabolites are closely related to the phenotype and are available from different human bio-fluids, metabolomics are candidates for non-invasive early detection of colorectal neoplasms. Objectives: We aimed to summarize current knowledge on performance characteristics of metabolomics biomarkers that are potentially applicable in a screening setting for the early detection of colorectal neoplasms. Design: We conducted a systematic literature search in PubMed and Web of Science and searched for biomarkers for the early detection of colorectal neoplasms in easy-to-collect human bio-fluids. Information on study design and performance characteristics for diagnostic accuracy was extracted. Results: Finally, we included 41 studies in our analysis investigating biomarkers in different bio-fluids (blood, urine, and feces). Although single metabolites mostly had limited ability to distinguish people with and without colorectal neoplasms, promising results were reported for metabolite panels, especially amino acid panels in blood samples, as well as nucleosides in urine samples in several studies. However, validation of the results is limited. Conclusions: Panels of metabolites consisting of amino acids in blood and nucleosides in urinary samples might be useful biomarkers for early detection of advanced colorectal neoplasms. However, to make metabolomic biomarkers clinically applicable, future research in larger studies and external validation of the results is required.

show abstract

“…Analysis of fatty acids and their metabolites was completed by 8045 series ultra‐high pressure liquid chromatography tandem mass spectrometry analysis (UPLS‐MS) (Shimadzu, Japan) coupled with C8 column (Phenomenex, USA). The condition of UPLS‐MS has been reported in previous studies 15,16 . In brief, mobile phase solutions were consisted of water (0.1% formic acid) and acetonitrile.…”

Section: Methodsmentioning

confidence: 99%

“…The condition of UPLS-MS has been reported in previous studies. 15,16 In brief, mobile phase solutions were consisted of water (0.1% formic acid) and acetonitrile. The gradient elution procedure of acetonitrile listed as followed: 10% (0 min)-25%…”

Section: Ultra-high Pressure Liquid Chromatography Tandem Mass Spectr...mentioning

confidence: 99%

Targeted fatty acid metabolomics to discover Parkinson's disease associated metabolic alteration

et al. 2021

Self Cite

View full text Add to dashboard Cite

The pathogenesis of Parkinson's disease (PD) remains to be elucidated, and the metabolomics analysis has the potential to identify metabolic profiles that are involved in PD pathogenesis. Here we applied a target metabolomics approach to measure the plasma levels of 158 fatty acid metabolites in a discovery cohort including 42 PD patients and 54 health volunteers, and found two upregulated (arachidonic acid and 13-hydroxy-octadecatrienoic acid) and eleven down-regulated (docosahexaenoic acid, lyso-platelet-activating factor, 12-hydroxy-eicosatetraenoic acid, dihydroxy-eicosatrienoic acids, dihidroxy-octadecenoic acids, 17,18-dihydroxyeicosatetraenoic acid, and hydroperoxy-octadecadienoic acids) metabolites as primary candidate marker of PD. A support vector machine algorithm with primary candidate marker was used in an independent validation cohort to identify PD. Arachidonic acid and 13-hydroxy-octadecatrienoic acid were evaluated as an effective tool in that area under the receiver operating characteristic curve reached 0.995 and 0.912 in the validation set for diagnosing PD from healthy volunteers.Besides, the sensitivity and specificity of arachidonic acid as diagnostic factor of PD in validation set were 100% and 94.10%. Similarly, the sensitivity and specificity of 13-hydroxy-octadecatrienoic acid were 100% and 82.40% for identifying PD. This target fatty acid metabolomics demonstrated a series of plasma fatty acid metabolite as PD candidate marker with high efficiency and provided insights into the understanding of PD metabolic regulation.

show abstract

Distinct differences in serum eicosanoids in healthy, enteritis and colorectal cancer individuals

Cited by 16 publications

References 52 publications

Understanding modulations of lipid mediators in cancer using a murine model of carcinomatous peritonitis

Understanding modulations of lipid mediators in cancer using a murine model of carcinomatous peritonitis

Metabolomics Biomarkers for Detection of Colorectal Neoplasms: A Systematic Review

Targeted fatty acid metabolomics to discover Parkinson's disease associated metabolic alteration

Contact Info

Product

Resources

About